Resource 01 · Strategy & Commercialisation
Product Commercialisation Readiness Framework
What must be demonstrated before an idea becomes a commercially viable, manufacturable and market-ready product?
Developed and curated by Shamim Quresh · Editorial methodology
Level 1 · Understand · about two minutes
The framework at a glance
A launch date is a planning constraint, not proof of readiness. Most product failures are not caused by a lack of effort but by decisions taken in the wrong order: artwork before claims are settled, tooling before the formula is stable, campaign spend before supply is reliable. A stage-gate structure makes the remaining uncertainty visible and assigns it to named people.
- Controlling question
- Should this product exist, and is it ready to launch?
- Key decision record
- Stage-gate decision log
- Role in the library
- Coordinates the overall lifecycle
- Applies to
- Consumer products in general, with examples from cosmetics and beverages. It is a planning aid: completing it does not guarantee safety, legal compliance or commercial success.
The 9 stages
Stage 01 of 9 · ends in a gate decision
Opportunity assessment
Is there a meaningful problem, and nothing obviously fatal?
Essential deliverables
- Opportunity thesis and assumption register
- Feasibility memo and project charter
- Product requirement specification
- Prototype register and test reports
- Master manufacturing instructions and supply plan
- Market release checklist and regulatory evidence index
- Launch dashboard and incident log
- Stage-gate decision records
Common mistakes
- Treating the launch date as evidence of readiness.
- Leaving regulatory scoping until artwork.
- Calling a gap 'conditional' when it is a safety or legal requirement.
- Modelling price without discounts, channel fees and returns.
- Buying tooling before the formula and pack are stable.
After reading, you should be able to
- Describe the nine stages and the evidence each gate requires.
- Distinguish Go, Conditional Go, Hold and Stop / Redesign, and explain why safety and legal requirements can never be conditional.
- Calculate contribution per unit, break-even units and a reorder point, and test them against downside scenarios.
- Plan overlapping workstreams without compressing safety work.
How it connects to the other frameworks
Level 2 · Study · the complete methodology
Work the method
Purpose and governing principle
Commercialisation is the disciplined conversion of a plausible opportunity into a product that can be lawfully sold, reliably supplied, economically sustained and credibly supported after launch. A launch date is a planning constraint, not proof of readiness. The correct question is not “Have all nine stages been ticked?” but “Is the residual uncertainty acceptable to the named decision-makers, on the basis of traceable evidence?”
Nine stages with explicit gates
| Stage | Core tasks | Essential inputs | Required outputs | Critical dependency / exit criterion |
|---|---|---|---|---|
| 1. Opportunity assessment | Define problem, category, user, alternatives, price corridor, unmet need; scan regulation and IP | Market observation, interviews, competitor samples, channel economics | Opportunity thesis, market map, assumption register, kill criteria | Evidence of a meaningful problem; plausible addressable demand; no obvious fatal prohibition |
| 2. Feasibility and business case | Estimate technical difficulty, bill of materials, factory fit, unit economics, cash-cycle and worst cases | Product concept, indicative suppliers, process options, regulatory scoping | Feasibility memo, rough target cost, risk-ranked project charter | A feasible path exists within capital, timing and risk tolerances |
| 3. Product requirements and concept freeze | Translate needs into measurable performance, user, packaging, claim, sustainability and market requirements | Consumer insight, feasibility, channel brief | Product requirement specification (PRS), target product profile, claim hypothesis list | Requirements have test methods, acceptance criteria and owners |
| 4. Development and proof of concept | Prototype formula/product, screen ingredients, evaluate packaging, run early tests and sensory studies | PRS, approved raw materials, lab capability | Prototype register, preliminary performance evidence, initial hazard assessment | At least one viable technical concept; unresolved risks documented |
| 5. Design verification and validation | Confirm technical requirements, fit-for-use, stability, safety, compatibility, scale-up assumptions and claim support | Prototype candidate, test plan, methods, representative materials | Verified specification, test reports, safety dossier inputs, validation summaries | Failures investigated; evidence sufficient for intended use and market |
| 6. Industrialisation and supply readiness | Select manufacturer, qualify suppliers, map process, assess capacity, set controls, perform transfer trials | Approved product design, packaging, equipment, suppliers | Master manufacturing instructions, specification hierarchy, trial report, supply plan | Factory can demonstrate controlled manufacture at intended scale |
| 7. Legal, quality and launch readiness | Complete market-specific records, label review, product notification/registration where applicable, logistics and recall preparation | Stable technical design, safety documentation, product labels, company/operator details | Market release checklist, quality agreement, regulatory evidence index, approved artwork | Named authorised release decision; market-specific obligations met |
| 8. Controlled launch | Pilot channels, monitor orders, complaints, returns, stock, repeat purchase and real-world product response | Released stock, trained teams, contingency plan | Launch dashboard, incident log, customer feedback, channel performance | Controlled distribution, active escalation routes and capacity to respond |
| 9. Post-launch optimisation | Track quality trends, demand, gross margin, experience, changes, adverse events and end-of-life | Field data, batch data, channel data, approved change procedures | Product review, CAPA/change actions, portfolio decision, revised forecast | Continue, improve, expand, pause or retire on evidence |
Gate decisions are not binary checkboxes
A gate review records one of four dispositions: GO, CONDITIONAL GO (only for explicitly bounded non-critical gaps), HOLD (obtain more evidence) or STOP/REDESIGN. A missing safety assessment, unresolved critical defect, prohibited ingredient or required market authorisation cannot be waived as a mere commercial exception. Conditional go must name the missing evidence, accountable owner, deadline, exposure limit and automatic stop condition.
Workstream dependencies
Regulatory scoping begins in stage 1, not stage 7. Claims research begins before formulation locks. Packaging compatibility begins while formulas are still adaptable. Manufacturer capability is checked before the laboratory falls in love with an unmanufacturable viscosity. Commercial photography and campaign spend are delayed until the product's appearance, pack and claims are sufficiently stable. These overlaps compress lead time without compressing safety work.
Stage-gate scorecard
Use five 0–4 ratings: consumer desirability, technical feasibility, unit economics, manufacturing robustness, market compliance. A rating of 0 means no evidence; 1 = conjecture; 2 = preliminary evidence; 3 = verified against defined criteria; 4 = repeatably demonstrated in a representative setting. The score is a discussion instrument, not an approval algorithm: a severe regulatory or safety deficit overrides a high aggregate score.
Quantitative commercial tools
- Contribution per unit = net realised selling price − variable product cost − variable fulfilment/channel cost − expected returns/allowances.
- Break-even units = launch-period fixed costs ÷ contribution per unit, provided contribution is positive.
- Reorder point = expected demand during replenishment lead time + safety stock. Estimate variability explicitly; do not copy arbitrary safety-stock percentages.
- Cash conversion exposure = when inventory and deposits are paid versus when customer cash is collected, including channel payment terms and minimum order quantities.
- Sensitivity triangle: recalculate the business case simultaneously for lower volume, higher cost and slower replenishment. Optimism compounds when assumptions are correlated.
Worked illustration — not a forecast. A product with net realised revenue of $18/unit and $10.50/unit in variable costs has $7.50 contribution. If attributable fixed launch costs total $15,000, break-even is 2,000 units before taxes and financing effects. If promotions lower realised revenue to $15 while costs rise to $11, contribution falls to $4 and break-even rises to 3,750 units. Pricing and supplier negotiations therefore belong in the same model.
Unconventional but disciplined problem-solving techniques
- Premortem laboratory. Convene formulation, brand, production, regulatory and logistics personnel. Imagine the launch failed in six months; each person writes the most likely cause. Convert the top causes into experiments and controls before committing to capital.
- Reverse the factory. Start with the customer's expected unboxing and use experience, then trace backward through fill volume, pump/tube behaviour, packaging line limits, formula rheology, ingredients and procurement. This uncovers requirements hidden by departmental silos.
- Constraint auction. Give each team a limited number of “constraint tokens” to allocate to cost, speed, sustainability, aesthetics, performance and risk. Explain why each constraint is expensive. This exposes conflicts before teams optimise different objectives.
- Evidence debt register. Treat every untested assumption like technical debt, with an owner and the cost of discovering it late. Prioritise high-impact, cheap-to-test uncertainties first.
- Smallest reversible experiment. Before buying production tooling, test one deliberately difficult failure mode using the smallest representative sample possible, then confirm representativeness before extrapolating.
- No-regrets parallelism. Run supplier discovery, early market interviews, claims scoping and packaging risk assessment simultaneously; sequence irreversible spend behind evidence gates.
Example deliverables and reusable template
Commercialisation decision record
| Field | Entry |
|---|---|
| Product / market / revision | [IDs] |
| Current stage / gate meeting | [Stage; date; reviewers] |
| Decision / rationale | [Go, conditional go, hold, stop; why] |
| Evidence reviewed | [Links to controlled versions] |
| Open critical risks | [ID; severity; owner; mitigation] |
| Financial sensitivity | [base / downside / extreme case] |
| Conditions and stop triggers | [metric; owner; due date] |
| Next stage deliverables | [named accountable person] |
Applying the framework
Opportunity assessment matrix
Score each criterion with the same 0–4 evidence scale used at the gates. The point is to expose where the evidence is thin, not to produce a single number.
| Criterion | Evidence that counts | Warning sign |
|---|---|---|
| Problem significance | Observed behaviour, workarounds people already pay for, unprompted complaints | Interest expressed only when the idea is described to them |
| Addressable demand | Purchase occasions you can count in a defined channel and geography | A national market-size figure with no route to the customer |
| Alternatives | Direct, indirect and non-consumption options mapped with prices | "No competitors" |
| Price corridor | Shelf and online prices of real alternatives; willingness-to-pay tested against a concrete offer | A price set only by working backwards from a target margin |
| Channel fit | Named retailer or channel requirements, margins and payment terms | Assuming a channel will list the product because it is good |
| Regulatory and IP scan | Product classification, restricted ingredients or claims and freedom-to-operate questions logged | Classification left until artwork |
| Fit with capability | Skills, partners and capital that exist or can realistically be secured | The plan depends on capabilities nobody has yet |
Technical feasibility matrix
| Question | What to examine | Typical evidence at stages 2–4 |
|---|---|---|
| Can it be made at all? | Format, key materials, known formulation or engineering limits | Literature, supplier technical data, bench prototypes |
| Can it be made to specification? | Each requirement in the product requirement specification and how it will be tested | Draft requirements-to-test matrix |
| Can it be made at scale? | Equipment, batch size, fill format and the manufacturer's capability | Manufacturer conversation, equipment list, trial plan |
| Can it be made at the target cost? | Bill of materials, yield assumptions, packaging and conversion cost | Indicative quotations, sensitivity ranges |
| Can it be sold in the intended markets? | Classification, ingredient status, labelling and registration routes | Requirements register entries with sources |
| Can it be supplied reliably? | Lead times, minimum order quantities, single-source materials | Supplier list with lead times and alternatives |
Risk register
Record each risk once and link it to the stage where it must be resolved.
| Field | Content |
|---|---|
| Risk ID | Stable identifier, for example RSK-014 |
| Description | Cause → event → consequence, in one sentence |
| Category | Safety, regulatory, technical, supply, commercial, reputational |
| Severity / likelihood / detectability | Rated with a documented rationale; a severe safety or legal risk is never averaged away |
| Owner | One named person |
| Response | Avoid, reduce, transfer or accept, with the specific action |
| Evidence of control | The record that shows the action worked |
| Gate | The stage-gate by which it must be closed or formally accepted |
| Status and review date | Open, controlled, closed, accepted |
Commercial readiness checklist
Before a stage 7 release decision, confirm with evidence rather than assertion:
- Product: specification approved; stability and compatibility conclusions recorded; open tests listed with their consequence.
- Safety and regulatory: market-specific obligations identified, met and indexed; responsible parties named; labels approved for each market.
- Supply: manufacturer and suppliers qualified; quality agreement signed; first production batches planned against forecast; reorder point calculated.
- Commercial: price, discount structure and channel terms reflected in the contribution model; downside case reviewed.
- Customer: product education, customer-service answers and complaint routes ready; returns process defined.
- Recall readiness: lot-to-customer traceability tested; contacts and decision rights agreed.
Launch dependencies
Some decisions cannot be finalised until others are stable. The most common critical path:
| This decision… | …depends on | Why |
|---|---|---|
| Final artwork | Formula revision, claims wording, market list, net contents | Every change to these alters the label |
| Claims wording | Substantiation evidence and market classification | A claim can change the regulatory category |
| Packaging order | Compatibility and dispensing results in the final pack | A compatible bulk can fail in the pack |
| Production booking | Transfer trial results and supplier lead times | The factory slot is wasted if materials are late |
| Campaign photography | Final pack, product appearance and approved claims | Reshoots are expensive and slow |
| Release decision | Batch record review, required market evidence, open deviations closed or assessed | Release is a quality decision, not a calendar date |
Running a premortem
- Agree the scenario: "It is six months after launch and the product has failed."
- Each participant writes, silently and independently, the single most likely cause.
- Read the causes aloud without discussion; cluster them.
- For each cluster, ask: what early signal would we see, and what is the cheapest test or control we could run now?
- Add the results to the risk register and the evidence debt register with owners and dates.
Reverse-engineering from the customer experience
Write the first five minutes of the customer's experience in concrete detail: opening the parcel, the weight in the hand, the first dispense, the feel on skin, the smell, the residue, the second use. Then ask what must be true at each upstream step for that experience to happen — fill weight and headspace, closure torque, viscosity range, ingredient grade, supplier lead time. Each answer becomes a requirement with an owner.
Failure scenarios and troubleshooting
| Symptom | Likely underlying cause | First response |
|---|---|---|
| Launch date fixed before requirements exist | Calendar treated as evidence of readiness | Re-baseline the plan from the critical path; make the date a constraint to test |
| Contribution turns negative after launch | Promotions, channel fees or returns missing from the model | Rebuild the unit model with net realised price and all variable costs |
| Artwork reprinted repeatedly | Claims, formula or market list changing after artwork started | Freeze claims and formula revision before artwork; link artwork to revision IDs |
| Factory cannot reproduce the laboratory sample | Scale-dependent process variables not transferred | Hold launch; run a witnessed transfer trial against the same critical quality attributes |
| Stock-out within weeks | Reorder point set without lead-time variability | Recalculate with observed demand and lead-time variation; review minimum order quantities |
| Conditional go never closes | Conditions without owner, deadline or stop trigger | Convert to hold until the condition is fully specified |
For the shared master-data keys, the five-question executive review and the 90-day implementation sequence, see the shared toolkit on the library page.
Level 3 · Apply · educational tools
Practise the method
These tools are teaching simulations. They use illustrative data, show their assumptions and are not validated scientific, regulatory or financial instruments.
Commercialisation roadmap and gate review
Select any of the nine stages to see its purpose, inputs, deliverables, dependencies, decision-makers, risks, evidence and exit criteria. Then hold a gate review: mark which exit checks have evidence and take one of four decisions.
Stage 01 of 9
Opportunity assessment
- Purpose
- Establish whether there is a meaningful problem worth solving, for a reachable customer, with no obvious fatal barrier.
- Key activities
- Define problem, category, user, alternatives, price corridor and unmet need; scan regulation and intellectual property.
- Required inputs
- Market observation, interviews, competitor samples, channel economics.
- Required deliverables
- Opportunity thesis, market map, assumption register, kill criteria.
- Dependencies
- None upstream. Regulatory scoping starts here, not at stage 7.
- Decision-makers
- Founder or sponsor, with commercial and technical leads.
- Risks
- Confirmation bias; mistaking interest for demand; missing a prohibition.
- Evidence required
- Observed behaviour and workarounds; counted purchase occasions; a classification scan.
- Exit criteria
- Evidence of a meaningful problem; plausible addressable demand; no obvious fatal prohibition.
- Common reasons for failure
- Opportunity defined by the founder's enthusiasm; no kill criteria written down in advance.
Show the decision record as text
Gate decision record (illustrative) Stage 1: Opportunity assessment Decision: Not yet taken Evidence in hand: none Outstanding: [critical] Product classification and any prohibited ingredients or claims scanned for each target market; Problem observed in real behaviour, not only in answers to a pitch; Alternatives, including doing nothing, mapped with prices; Kill criteria written before more money is spent
Limits of this tool. A teaching set of exit checks, not a complete checklist. The tool enforces one rule from the framework: a safety-critical or legally mandatory gap can never be passed as a conditional go. Nothing you enter is saved or sent.
Commercial feasibility calculator
Change price, discounts, costs, fees, launch costs, order quantity and lead time, and watch contribution, break-even, revenue and inventory exposure move across conservative, base and optimistic cases.
| Result | Conservative | Base | Optimistic |
|---|---|---|---|
| Net realised price | $17.00 | $18.00 | $18.00 |
| Variable cost per unit | $11.55 | $10.50 | $10.18 |
| Contribution per unit | $5.45 | $7.50 | $7.82 |
| Contribution margin | 32.1% | 41.7% | 43.4% |
| Break-even units | 2,753 | 2,000 | 1,920 |
| Weeks to break even | 32.8 | 16.7 | 12.8 |
| Revenue over 26 weeks | $37,128 | $56,160 | $70,200 |
| Result after fixed costs, 26 weeks | −$3,097 | $8,400 | $15,479 |
| Reorder point (units) | 1,179 | 1,100 | 1,340 |
| of which safety stock | 171 | 140 | 140 |
| Weeks of cover from initial order | 35.7 | 25.0 | 20.0 |
| Cash tied up in initial order | $24,750 | $22,500 | $21,825 |
| Initial stock unsold after 26 weeks | 816 units ($6,732) | None | None |
Sensitivity: break-even units in the base case
| Price ↓ / Variable cost → | −10% | As entered | +10% |
|---|---|---|---|
| −10% | 2,223 | 2,632 | 3,226 |
| As entered | 1,755 | 2,000 | 2,326 |
| +10% | 1,450 | 1,613 | 1,819 |
Read across a row to see how cost negotiations move break-even; read down a column for pricing. The conservative scenario is the framework's sensitivity triangle: lower volume, higher cost and slower replenishment at the same time, because optimism compounds when assumptions are correlated.
Assumptions and calculation method
- Net realised price = list price × (1 − discounts).
- Contribution per unit = net realised price − production − packaging − fulfilment − channel fees − returns and allowances.
- Channel fees and returns are applied as a percentage of net realised price; returned units are assumed unsaleable.
- Break-even units = fixed launch costs ÷ contribution per unit, only when contribution is positive. Before tax and financing.
- Reorder point = weekly demand × lead time + safety stock. Safety stock = 1.65 × weekly standard deviation × √(lead time in weeks): roughly a 95% chance of not running out in a lead time, assuming fairly steady, normally distributed demand and a fixed lead time.
- Conservative case: 70% of the volume, variable costs +10%, discounts +5 points, lead time ×1.5. Optimistic case: 125% of the volume, variable costs −3%. These adjustments are illustrative.
- Not modelled: payment terms and cash timing, minimum order quantities, shelf life, taxes and duties.
Limits of this tool. Uses the framework’s formulas with stated assumptions. It ignores tax, financing, payment terms and minimum order quantities, and it is not a forecast or financial advice.
Working templates
Download the templates
Each file includes instructions, field definitions and example entries. Example entries are marked ILLUSTRATIVE and describe fictional products. All ten templates are listed on the library page.
- Download Product Commercialisation Stage-Gate Checklist Excel workbook (.xlsx)
Product Commercialisation Stage-Gate Checklist
Nine stages with exit criteria, evidence links and status, a 0–4 readiness scorecard and a gate decision record.
- Download Product Requirements Specification Word document (.docx)
Product Requirements Specification
Turns needs into measurable requirements, each with a test method, acceptance criterion and owner.
References and further reading
Sources
Primary sources for verification. Listing a source is not a claim that every requirement in it applies to every product. Recheck laws, standards and market dates before commercial use.
Voluntary standard (guidance note)
The process approach in ISO 9001:2015 (opens in a new tab)
Explains the process approach, risk-based thinking and the Plan-Do-Check-Act cycle. Check for a newer edition of ISO 9001 before relying on clause references.
Pharmaceutical methodology
Q8, Q9 and Q10 are designed to work together to support science- and risk-based approaches to quality.
Links and summaries last checked 18 November 2026.
Editorial methodology
These frameworks were developed and curated by Shamim Quresh, drawing on her professional practice in product development, formulation, manufacturing, branding and compliance.
They rely on published standards, regulations and established scientific principles, cited where they are used. That research and those publications are the work of their own authors and publishers.
AI tools assisted with drafting, structuring and checking the text, the interactive tools and the templates. Content is reviewed by Shamim before publication, and regulatory references were checked against official sources on the review date shown.
Worked examples, scenarios, results and data are illustrative. They do not describe experiments, tests or studies that Shamim has carried out, and no regulatory assessment of any product has been made.
Want to apply a framework to your own product?
I use these methods in consultancy work on product development, commercialisation, manufacturing and compliance. Tell me what you are building and where it is stuck.